The latest UK peptide medicine news — Mounjaro, Ozempic, retatrutide and NHS policy updates, tracked and explained in plain English as they happen.
Retatrutide has been one of the most talked-about medicines in weight loss research for the past two years. This week, Eli Lilly confirmed it will allow a limited number of patients to apply for early access to the drug before it receives full regulatory approval in the United States. According to STAT News and Reuters,…
Retatrutide has been one of the most closely watched medications in weight loss communities for the past two years. So when Eli Lilly published positive topline results from two major Phase 3 trials in July 2025, the conversations lit up immediately. People wanted to know what these numbers actually mean, whether the cardiovascular concerns some…
BPC-157 has been one of the most discussed compounds in these communities for years. So when news broke that a US advisory panel had voted to recommend broader access to it and several other peptides, the reaction was immediate and understandable. People wanted to know whether this changes anything in the UK. The short answer…
A study reported by Reuters in July 2026 is raising important questions about how GLP-1 weight loss medicines affect older adults. Researchers are calling for closer monitoring of frailty, muscle loss and malnutrition in patients using these treatments, even when weight loss appears to be going well. For UK women in their forties and fifties…
A landmark systematic review published in the BMJ in July 2026 compared 19 obesity medicines across 262 clinical trials. According to the BMJ, tirzepatide and CagriSema produced the largest estimated weight reductions. However, injectable semaglutide currently holds the strongest evidence for reducing deaths, heart attacks and kidney disease. The findings are reshaping how clinicians and…
The launch of Wegovy tablets in UK pharmacies was a significant moment for people seeking weight loss treatment. But according to regulators and pharmacists, counterfeit Wegovy pills are already circulating through unregulated online sellers. This pattern is not new. It happens after almost every major medicine launch in the UK. Understanding why it happens and…
Superdrug launched oral semaglutide in the UK in July 2026, becoming the first provider to offer the Wegovy pill commercially following regulatory sign-off from the MHRA. Eligible patients can now access the treatment through an online clinical assessment via Superdrug’s health platform, without needing an injection. According to LADbible, experts are calling this the start…
Eli Lilly, the American pharmaceutical giant behind Mounjaro, has confirmed it intends to launch its oral weight loss pill in Europe and the United Kingdom within the next 12 to 18 months. According to Reuters, the company made this announcement in June 2026 as part of a broader strategic shift towards tablet-based obesity treatments. This…
A genuinely new type of weight loss medicine is making its way through the UK approval process. Orforglipron, branded as Foundayo and made by pharmaceutical company Eli Lilly, is an oral once-daily pill that activates the same hunger-regulating system as Ozempic and Mounjaro — but it is not a peptide and does not require an…
The UK’s medicines regulator has approved a daily weight loss tablet for the first time. The Wegovy pill — an oral version of the drug semaglutide — has been given the green light for adults with obesity. Private prescriptions are expected to be available within weeks. This development was announced on 11 June 2026. According…